FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to an antibody, which binds itself with EphA2 antigen associated with a tumour.
EFFECT: invention can be used for therapy, diagnosing and screening of cancer.
4 cl, 83 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALPHA-V BETA-8-BINDING ANTIBODIES | 2012 |
|
RU2614252C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| MONOCLONAL ANTIBODIES TO CD44, INTENDED FOR USE IN TREATING SQUAMOUS CELL CARCINOMA OF THE HEAD AND THE NECK | 2011 |
|
RU2599447C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| IL-12/P40 BINDING PROTEINS | 2006 |
|
RU2461571C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| SOLUBLE CEA-STABLE PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2573893C2 |
| SOLUBLE CD3 STABLE PHARMACEUTICAL COMPOSITIONS | 2006 |
|
RU2426743C2 |
| COMPOUNDS | 2007 |
|
RU2466139C2 |
Authors
Dates
2016-09-27—Published
2011-07-22—Filed